TAEST 16001

Next Previous
Drug Profile

TAEST 16001

Alternative Names: Anti-NY-ESO-1 TCR transduced T cells; NY-ESO-1-specific TCR affinity enhancing specific T cell therapy; NY-ESO-1-transduced T-cells - Guangzhou-Pharmaceutical; TAEST-16001; TCR affinity enhancing specific T cell therapy

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Guangzhou Institute of Respiratory Disease
  • Developer Guangdong Xiangxue Precision Medical Technology; Guangzhou Institute of Respiratory Disease; Guangzhou Xiangxue Pharmaceuticals; Xiangxue Life Science Research Center
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 16 Mar 2018 Guangdong Xiangxue Precision Medical Technology and Sun Yat-sen University plans a phase I trial for Osteosarcoma (Second-line therapy or greater, Late-stage disease, In adolescents, In adults, In the elderly) and Soft tissue sarcoma (Second-line therapy or greater, Late-stage disease, In adolescents, In adults, In the elderly) in March 2018 (NCT03462316)
  • 17 May 2017 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (IV) (NCT03159585)
  • 20 Jan 2017 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Recurrent) in China (Parenteral) (NCT03029273)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top